Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial.
- Resource Type
- Article
- Source
- Journal of Clinical Oncology; 2/1/2023 Supplement 1, Vol. 41, pTPS634-TPS634, 1p
- Subject
- Language
- ISSN
- 0732183X